<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905212</url>
  </required_header>
  <id_info>
    <org_study_id>RC18G004</org_study_id>
    <nct_id>NCT04905212</nct_id>
  </id_info>
  <brief_title>A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Multicenter Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical study&#xD;
      to evaluate the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of&#xD;
      IgA nephropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IgA nephropathy is a kidney disease in which IgA, a protein meant to defend the body against&#xD;
      foreign invaders, accumulates in the kidneys and damages them. This study will seek to&#xD;
      determine the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of&#xD;
      IgA nephropathy.&#xD;
&#xD;
      The study is composed of 2 parts: a screening period and a double-blind treatment period.&#xD;
      Subjects with confirmed IgA nephropathy within 8 years will be enrolled and randomized 1:1:1&#xD;
      to Telitacicept 160 mg, Telitacicept 240 mg, or placebo (10 per arm).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 24-hour urine protein at Week 24.</measure>
    <time_frame>Week 24</time_frame>
    <description>Change from baseline in urine protein over 24 hours to Week 24 will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Change from baseline in eGFR by visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Urine protein-to-creatinine ratio (UPCR) and Urine albumin-to-creatinine ratio (UACR)</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Change from baseline in Urine protein-to-creatinine ratio (UPCR) and Urine albumin-to-creatinine ratio (UACR) by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in immunological parameters</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Changes from baseline in Immunoglobulins (IgA, IgG, IgM), B lymphocytes (CD19+), complements (C3, C4)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The incidence and severity of adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number and intensity of adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity endpoints</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Anti-drug antibody (ADA), incidence, titers and duration</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomaker endpoints serum concentration</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>BLyS serum concentration, APRIL serum concentration, and BLyS-drug complex</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic endpoints</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Free Telitacicept serum concentration and total Telitacicept serum concentration</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Telitacicept 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telitacicept 160mg subcutaneous injection once weekly, and a total of 24 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telitacicept 240mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telitacicept 240mg subcutaneous injection once weekly, and a total of 24 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous injection once weekly, and a total of 24 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telitacicept 160mg</intervention_name>
    <description>Subcutaneous injection Telitacicept 160mg. The injection site can be at the thigh, abdomen, or upper arm.</description>
    <arm_group_label>Telitacicept 160mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telitacicept 240mg</intervention_name>
    <description>Subcutaneous injection Telitacicept 240mg. The injection site can be at the thigh, abdomen, or upper arm.</description>
    <arm_group_label>Telitacicept 240mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection placebo. The injection site can be at the thigh, abdomen, or upper arm.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. IgA nephropathy confirmed by pathological biopsy within 8 years prior to&#xD;
             randomization;&#xD;
&#xD;
          2. Male or female aged ≥ 18 years old and ≤ 70 years old;&#xD;
&#xD;
          3. Average 24-hour urine total protein ≥ 1 g/24 h&#xD;
&#xD;
          4. Estimated GFR (using the CKD-EPI formula) &gt; 30 mL/min per 1.73 m^2;&#xD;
&#xD;
          5. Stabilized AEI/ARB medications, diuretics, or other antihypertensive therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with clinically significant abnormal laboratory tests at screening;&#xD;
&#xD;
          2. Evidence of rapid eGFR decrease &gt; 15 ml/min during screening;&#xD;
&#xD;
          3. Renal or other organ transplantation prior to, or expected during, the study;&#xD;
&#xD;
          4. Patients with secondary IgA nephropathy;&#xD;
&#xD;
          5. Patients with nephrotic syndrome, crescentic nephritis minimal change nephropathy with&#xD;
             IgA deposition, or other pathological or clinical types of renal diseases that may&#xD;
             confound the study data interpretation;&#xD;
&#xD;
          6. Patients with history of any severe unstable cardiovascular and cerebrovascular events&#xD;
             within 12 weeks prior to screening;&#xD;
&#xD;
          7. Immunocompromised individuals.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Remegen Biosciences</last_name>
    <phone>1-301-284-1015</phone>
    <email>Remegen.MD@remegen.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Remegen Site #5</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #4</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #13</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #14</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #6</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #10</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95687</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #8</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #16</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #12</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #15</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #17</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #2</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #7</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #3</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79925</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #11</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remegen Site #1</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

